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ABSTRACT
Introduction: Statins have several pleiotropic effects including its primary effect of lipid lowering that is important 
to prevent cardiovascular disease (CVD). Subjects often have heterogeneous responses to statin. This study aims to 
determine the biochemical effects of statins on lipid parameters among newly diagnosed dyslipidaemia subjects. 
Methods: This was a prospective observational study involving 118 newly diagnosed adults with dyslipidaemia from 
three government health clinics in Selangor, Malaysia. Biochemical analyses including fasting lipid profile [triglyceride 
(TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol 
(HDL-C)] and apolipoproteins (apoA1, apoB) were taken at baseline and follow-up after a month on statin. Results: 
Majority of subjects (61.9%) were prescribed with lovastatin, with the rest on simvastatin. At baseline, the median 
values for all lipid profile parameters (TC, LDL-C, HDL-C) and non-conventional lipid parameters (LDL-C:HDL-C 
ratio, non-HDL-C, TC:HDL-C ratio, apoB:apoA1 ratio) were deranged except for TG and apoA1. On follow up, all 
parameters showed median values within the reference range except for HDL-C, non-HDL-C and TC:HDL-C ratio. 
There was significant difference in the effect of statins on lipid parameters including predictors of cardiovascular risk, 
simvastatin having better effects. Conclusions: Different statins have varying effects on lipid parameters. Simvastatin 
showed significantly better effects compared to lovastatin. Non-HDL value should be included in the standard lipid 
profile report given its ease of use and implementation as it’s both a marker of coronary artery disease (CAD) risk 
stratification as well as an established determinant of goal attainment during therapy.
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INTRODUCTION
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG 
CoA) reductase inhibitors, have several pleiotropic 
effects including its primary effect of lipid lowering that 
is important to prevent cardiovascular disease (CVD) (1). 
There are various types of statins prescribed worldwide 
such as atorvastatin (Lipitor and Torvast), simvastatin 
(Zocor and Lipex), lovastatin (Mevacor, Altocor and 
Altoprev), pitavastatin (Livalo and Pitava), rosuvastatin 
(Crestor), fluvastatin (Lescol) and pravastatin (Pravachol, 
Lipostat and Selektine) (1).  Subjects often have 
heterogeneous responses to statin. This suggests the 
possibility of interindividual variability in response to 
statin treatment.
Accordingly, this study aimed to determine the 
biochemical effects of statins prescribed in primary 
health care setting on lipid profile [triglyceride (TG), 
total cholesterol (TC), low density lipoprotein cholesterol 
(LDL-C) and high density lipoprotein cholesterol 
(HDL-C)] and non-conventional lipid parameters 
namely LDL-C:HDL-C ratio, non-HDL-C, TC:HDL-C 
ratio, apolipoproteins (apoA1, apoB) and apoB:apoA1 
ratio. ApoB has been proven to be highly correlated 
with the number of LDL-C particles, including very 
low density lipoprotein cholesterol (VLDL-C). Thus, an 
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elevated apoB has been shown to be the best prognostic 
factor of acute coronary events and deaths due to CVD 
(2, 3). Non-HDL-C is a result of TC minus HDL-C. 
There is a 1:1 correlation between the 1% non-HDL-C 
lowering effect and coronary artery disease (CAD) risk 
reduction by statin, which indicates that non-HDL-C 
plays an important role in the prevention and treatment 
of CVD (4). The TC:HDL-C ratio, which is also known as 
the atherogenic or Castelli index has a greater predictive 
value for CVD events compared to isolated parameters 
alone (3). ApoB:apoA1 ratio is a stronger CVD risk 
predictor compare to the TC:HDL-C ratio and LDL-
C:HDL-C ratio (5). The apoB:apoA1 ratio reflects the 
balance between two completely opposite processes; 
the transport of cholesterol to peripheral tissues, with its 
subsequent arterial internalisation, and reverse transport 
to the liver. Therefore, both of these apolipoproteins will 
separately provide information for detecting high-risk 
individuals (3, 6, 7).
MATERIALS AND METHODS
Study design 
This prospective observational data is part of a study 
(unpublished) where the main aim was to determine 
the association between SLCO1B1 RS4363657 
polymorphism and muscle aches and pains (a known 
side-effect of statins) in Malaysian dyslipidaemia patients 
prescribed with statins. This study was conducted from 
September 2013 to April 2015 involving 118 subjects 
from three government health clinics in the state of 
Selangor, Malaysia, namely  Kajang Health Clinic, 
Bandar Baru Bangi Health Clinic and Dengkil Health 
Clinic. As such, sample size calculation for hypothesis 
testing purpose was done using the prevalence of 
muscle aches and pain (P1=0.07) and severe myopathy 
(P2=0.005) [8]. The determination of sample size for 
this study was based on the requirement to achieve 95% 
confidence level to detect muscle aches and pain and 
gave a final sample size of 104 subjects. Malaysian adult 
patients aged 18 years old and above were recruited into 
this study. These patients were newly diagnosed with 
dyslipidaemia and were prescribed with statin for the 
first time. Subjects excluded from the study were those 
i) with known dyslipidaemia and already on statin; ii) 
with known cause of secondary dyslipidaemia such as 
hypothyroidism, nephrotic syndrome, chronic kidney 
disease, cholestasis iii) with pre-existing musculoskeletal 
problems, neuropathy or neuromuscular disorders and 
iv) receiving any concomitant medications known to 
cause or exacerbate dyslipidaemia (thiazides, beta-
blockers, corticosteroids, oral contraceptive pill) or cause 
myopathy (corticosteroids, penicillamine, lithium).
Data collection
Subjects were recruited on their first health screening 
visit at the clinics. Fasting blood investigations were 
taken at 8 am and reviewed in the afternoon on the same 
day. At baseline, statin commencement was based on 
the clinician’s discretion, following a detailed clinical 
history, physical examination and review of blood results. 
Statins prescribed in the government health clinics were 
commonly lovastatin and simvastatin with other statins 
being restricted for specialist prescription. A detailed 
information sheet on the study and verbal explanation by 
the researcher were given to eligible subjects. Subjects 
who agreed to participate also provided written consent. 
Subject’s sociodemographic details, medical history and 
type and dose of statin prescribed by the clinician were 
recorded into the proforma. Anonymity was maintained 
throughout the study. All subjects were then followed 
up at one (1) month for repeat blood investigations. 
Biochemical analysis 
At baseline and one month follow-up, five (5) mls of 
blood was withdrawn from the subject and analysed for 
fasting serum lipids (TG, TC, LDL-C, HDL-C), apoA1 
and apoB. The biochemical analyses were performed 
on an automated biochemistry analyser, Cobas c311 
Analyser (Hitachi Roche, Germany) in the Chemical 
Pathology Laboratory, Faculty of Medicine and Health 
Sciences, Universiti Putra Malaysia. Calibration and 
quality control were done as per the manufacturer’s 
instructions prior to each analysis.
Statistical analysis
As all data were not normally distributed, median and 
interquartile range (IQR) were calculated and non-
parametric analysis was done. Chi-square test was used 
to determine the association between sociodemographic 
factors and clinical characteristics with statins. Lipid 
parameters on the first appointment and subsequent 
follow-up appointment for statins were analysed using 
Wilcoxon Signed Rank Test, which is designed for 
use with repeated measures (lipid profile numerical 
parameters), that is when subjects are measured on two 
occasions (first and follow up appointments). Finally, 
the median difference in lipid parameters between the 
first and follow up appointments for statins was analysed 
using Mann Whitney Test. A p value of less than 0.05 was 
considered to be statistically significant. Data analyses 
were completed using the standard statistical software 
package, IBM SPSS Statistics for Windows, Version 22.0 
(Armonk, NY: IBM Corporation).
Ethics
Medical Research and Ethic Committee, Ministry of 
Health Malaysia ((NMRR-12-1307-13534) and the 
Ethics Committee for Research Involving Human 
Subjects Universiti Putra Malaysia (ref: UPM/FPSK/100-
9/2-MJKEtika/JPAT Sept(12)05 dated 18th November 
2012) approved the study. 
RESULTS 
A total of 136 eligible subjects were identified during 
the initial appointment. However, 18 subjects (13.2%) 
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Table I. Sociodemographic factors and clinical 
characteristics of study population (n = 118).
Variable Number n = 118 (%)
Gender 
 Male 
 Female 
74 (63)
44 (37)
Ethnicity 
 Malay 
 Indian 
 Chinese 
85 (72)
17 (14.4)
16 (13.6)
Age Group (years old) 
 18-40
 >40
31 (26.3)
87 (73.7)
BMI* 
 Underweight 
 Normal 
 Overweight 
 Obese 
2 (1.7)
32 (27.1)
58 (49.2)
26 (22.0)
Blood Pressure** 
 Normal 
 Prehypertension 
 Hypertension 
22 (18.6)
58 (49.2)
38 (32.2)
Medical History 
 No 
 Yes 
   HPT only 
   DM only 
   HPT and DM 
46 (39)
72 (61)
45 (38.1)
16 (13.6)
11 (9.3)
Smoking History 
 Smoker 
 Non-smoker 
24 (20.3)
94 (79.7)
Type and Dose of Statin 
  Lovastatin 20 mg
  Simvastatin 20 mg
73 (61.9)
45 (38.1)
BMI = body mass index; HPT = hypertension; DM = diabetes 
mellitus; *Based on the International Classification of adult 
underweight, overweight and obesity according to BMI (kg/
m2) by World Health Organization (WHO): underweight 
(<18.5); normal (18.5-24.9); overweight (25-29.9); obese 
(≥30).**Based on recommendations of the Seventh Report 
of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 7): 
Normal (Systolic: <120 and Diastolic: < 80); Prehypertension 
(Systolic: 120-139 and/or Diastolic: 80-89); Hypertension 
(Systolic: ≥140and/or Diastolic: ≥ 90) 
dropped out for various reasons, resulting in a final 
number of 118 subjects (86.8%). The common reasons 
for drop out were refusal to continue with the study 
with no particular explanation or they had moved to 
another area. Majority of study population consists of 
Malay (72%), males (63%) in the age group of above 
40 years old (73.7%). The mean age of subjects was 
49.0 ± 12.2 years old. Almost half of the subjects were 
overweight with a mean BMI of 27.4 ± 4.6 kg/m2 and 
were prehypertensive (Table I). There were significant 
differences between age group, ethnicity, blood 
pressure, medical history and smoker status between 
patients on lovastatin and simvastatin (Table II).  
Majority of subjects (61.9%) were prescribed with 
lovastatin, with the rest on simvastatin. At baseline 
for total study population, the median values for all 
lipid profile parameters (TC, LDL-C, HDL-C and non-
HDL-C) were deranged except for TG, apoA1 and apoB 
(for males only) [Table III]. Deranged values here are 
defined as values not within the reference range for 
respective lipid parameters. It is not values that are not 
within therapeutic target levels as per clinical practice 
guidelines as 4 weeks may be too soon for values to 
change drastically.  On follow up, all parameters showed 
median values within the reference range except for 
HDL-C, non-HDL-C and TC:HDL-C ratio (Table III). 
There was significant difference in these changes within 
the total study population as well as for lovastatin 
(Table IV) and simvastatin (Table V), respectively [p < 
0.05] except for Apo A1. HDL-C showed no significant 
difference for total study population and lovastatin 
where it decreased further on follow up whereas it 
showed a significant increase for simvastatin at follow 
up. This data is further supported by significant median 
difference in lipid parameters between first and follow-
up appointments for statins, with simvastatin showing 
better effects (Table VI).
DISCUSSION
Although these statins have been in the market for 
decades, there is limited data with respect to lovastatin 
and none for the Malaysian population, where it is still a 
first-line statin in primary care. However, it was towards 
the end of this study that lovastatin was withdrawn from 
the government health clinics but it is still prescribed at 
private general practice. This may be due to the improved 
cost of simvastatin and the greater effectiveness of 
simvastatin as compared to lovastatin, as found in this 
study, making it more feasible to be prescribed.  Prices 
in Malaysia range for simvastatin from 0.21 - 0.50 cents/
tablet (1000 tabs) to a slightly higher price for smaller 
packaging of 30s and 100s. For lovastatin only one dose 
is available (20 mg) and the prices are 0.57 cents/tab 
(500 tabs), 0.86 cents / tab (100 tabs) and 0.93 cents/tab 
(30 tabs) (9).
On follow up post one month on statin, though non-
HDL-C and TC:HDL-C ratio median values were not 
within the reference range, it was of decreasing trend. 
Paradoxically, the HDL-C value decreased within a 
month on statin for total study population and lovastatin 
but this change was statistically not significant. Patients 
on simvastatin, however, showed a significant increase 
in HDL-C on follow-up but not to the target value of 
more than 1. This could probably be attributed to the 
short follow-up of 4 weeks.
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Table II. Association between sociodemographic factors and clinical characteristics with statins 
Variable Lovastatin
n=73 
Simvastatin
n=45 χ2 p value
Gender n (%)
 Male 
 Female 
41 (55.4) 
32 (72.7)
33 (44.6) 
12 (27.3)
3.509 0.061
Ethnicity n (%)
 Malay 
 Indian 
 Chinese 
46 (54.1)
14 (82.4)
13 (81.3)
39 (45.9)
3 (18.8)
3 (17.6)
7.736 0.021*
Age Group (years old) n (%)
18-40
>40 
10 (32.3)
63 (72.4)
21 (67.7)
24 (27.6)
15.621 0.000*
BMI** n (%)
 Underweight 
 Normal 
 Overweight 
 Obese 
2 (100)
23 (71.9)
31 (53.4)
17 (65.4)
0 (0)
9 (28.1)
27 (46.6)
9 (34.6)
4.470 0.215
Blood Pressure*** n (%)
 Normal 
 Prehypertension 
 Hypertension 
7 (31.8)
39 (67.2)
27 (71.1)
15 (68.2)
19 (32.8)
11 (28.9)
10.489 0.005*
Medical History n (%)
 No 
 Yes 
   HPT only 
   DM only 
   HPT and DM 
14 (30.4)
38 (84.4)
11 (68.8)
10 (90.9)
32 (69.6)
7 (15.6)
5 (31.3)
1 (9.1)
33.240 0.000*
Smoking History n (%)
 Smoker 
 Non-smoker 
7 (29.2)
66 (70.2)
17 (70.8)
28 (29.8)
13.653 0.000*
Pearson Chi-square test; *p < 0.05 is significant 
BMI = body mass index; HPT = hypertension; DM = diabetes mellitus; **Based on the International Classification of adult 
underweight, overweight and obesity according to BMI (kg/m2) by World Health Organization (WHO): underweight (<18.5); 
normal (18.5-24.9); overweight (25-29.9); obese (≥30).***Based on recommendations of the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): Normal (Systolic: <120 and 
Diastolic: < 80); Prehypertension (Systolic: 120-139 and/or Diastolic: 80-89); Hypertension (Systolic: ≥140and/or Diastolic: ≥ 90) 
When comparing the median difference between the 
statins (Table VI), simvastatin showed significantly 
better effects on all studied lipid parameters. There are 
not many previous studies comparing lovastatin with 
other statins, locally and internationally. One study by 
Frohlich et al 20 years ago, compared the short-term 
efficacy and tolerability of lovastatin and simvastatin 
in the management of primary hypercholesterolaemia. 
In contrast to our study, the conclusion was that there 
were no significant differences between lovastatin and 
simvastatin in the treatment of moderate and severe 
primary hypercholesterolaemia (10). On the other 
hand, a more recent study by Schaefer et al. indirectly 
indicated that the same dose of simvastatin was more 
efficient in lowering LDL-C and non-HDL-C compared 
to lovastatin. This study was done by comparing the 
efficacy of atorvastatin with other statins (fluvastatin, 
pravastatin, lovastatin, and simvastatin) in the fasting 
and fed states. The efficacy of the same dose in the same 
patients of lovastatin and simvastatin were about 60%, 
and 85% of the efficacy of atorvastatin, respectively (2).
Most interestingly, significant improvement was 
observed in non-conventional lipid parameters 
(LDL:HDL-C ratio, non-HDL-C, TC:HDL-C ratio, 
apoA1, apoB, and apoB:apoA1 ratio), which are better 
predictors of cardiovascular risk. Both apoB and non-
HDL-C have been shown to be valuable parameters in 
risk stratification compared to LDL-C (11). However, 
some evidence suggests apoB is a better marker than 
non-HDL-C since apoB represents the total number of 
circulating atherogenic particles whereas non-HDL-C 
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Table III. Laboratory parameters of study population (n = 118)
Parameter First Appointment Follow Up Reference 
Range** Z p valueMedian 
(IQR)
Min-Max Median 
(IQR)
Min-Max
TC (mmol/L) 6.39(1.20) 4.43-12.10 4.37(1.72) 1.87-7.75 < 5.20 -9.239 0.000*
LDL (mmol/L) 3.53(0.78) 1.36-6.85 2.16(1.21) 0.62-4.73 < 2.60 -9.333 0.000*
HDL (mmol/L) 0.81(0.31) 0.40-1.73 0.75(0.42) 0.30-1.84 ≥ 1.10 0.000 1.000
TG (mmol/L) 1.66(0.95) 0.57-8.66 1.28(1.21) 0.07-5.82 < 1.70 -5.849 0.000*
LDL:HDL 4.36(1.96) 1.35-9.88 2.84(1.34) 0.57-8.02 < 3.0 -8.917 0.000*
Non-HDL (mmol/L) 5.57(1.29) 3.66-11.54 3.51(1.71) 1.31-7.16 < 3.35 -9.329 0.000*
TC:HDL 7.88(3.03) 3.87-21.61 5.56(2.54) 2.32-15.03 < 4.0 -8.220 0.000*
ApoA1 (g/L) 1.37(0.47) 0.65-2.92 1.25(0.41) 0.72-2.99 Female: 
1.04-1.63
Male: 
1.09-1.72
-0.275 0.783
ApoB (g/L) 1.26(0.31) 0.59-2.41 0.86(0.36) 0.28-1.91 Female:
0.6 -1.17
Male: 
0.66-1.33
-9.061 0.000*
ApoB:ApoA1 ratio 0.92(0.35) 0.38-2.10 0.69(0.24) 0.22-1.50 Female: < 0.7
Male: < 0.8
-9.098 0.000*
Wilcoxon Signed Rank Test; *p < 0.05 is significant 
y/o = years old; TC = total cholesterol; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol; TG 
= triglyceride; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B
**Roche Diagnostic reference ranges for adults
Table IV. Laboratory parameters of study population on lovastatin (n =73)
Parameter First Appointment Follow Up Reference 
Range** Z p valueMedian 
(IQR)
Min-Max Median 
(IQR)
Min-Max
TC (mmol/L) 6.20(1.00) 4.50-12.10 4.50(1.94) 1.87-7.75 < 5.20 -7.140 0.000*
LDL (mmol/L) 3.48(0.95) 1.85-5.06 2.26(1.29) 0.62-4.73 < 2.60 -7.317 0.000*
HDL (mmol/L) 0.82(0.36) 0.40-1.73 0.72(0.40) 0.30-1.84 ≥ 1.10 -1.204 0.229
TG (mmol/L) 1.77(1.03) 0.57-8.66 1.25(1.28) 0.07-5.82 < 1.70 -4.727 0.000*
LDL:HDL 4.21(1.79) 1.35-9.88 2.91(1.60) 0.57-8.02 < 3.0 -6.726 0.000*
Non-HDL (mmol/L) 5.36(1.16) 3.93-11.54 3.62(1.80) 1.31-7.16 < 3.35 -7.237 0.000*
TC:HDL 7.75(3.10) 3.87-21.61 5.94(2.60) 2.75-15.03 < 4.0 -5.943 0.000*
ApoA1 (g/L) 1.37(0.41) 0.65-2.92 1.33(0.42) 0.72-2.99 Female: 
1.04-1.63
Male: 
1.09-1.72
-0.144 0.886
ApoB (g/L) 1.26(0.33) 0.59-2.02 0.86(0.43) 0.28-1.86 Female:
 0.6 -1.17
Male: 
0.66-1.33
-6.714 0.000*
ApoB:ApoA1 ratio 0.92(0.32) 0.38-1.57 0.69(0.28) 0.22-1.50 Female: < 0.7
Male: < 0.8
-6.785 0.000*
Wilcoxon Signed Rank Test; *p < 0.05 is significant 
y/o = years old; TC = total cholesterol; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol; TG 
= triglyceride; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B
**Roche Diagnostic reference ranges for adults
Mal J Med Health Sci 14(1): 7-14, Jan. 201812
Malaysian Journal of Medicine and Health Sciences (ISSN 1675-8544)
Table V. Laboratory parameters of study population on simvastatin (n =45)
Parameter First Appointment Follow Up Reference 
Range** Z p valueMedian 
(IQR)
Min-Max Median 
(IQR)
Min-Max
TC (mmol/L) 6.70(0.90) 4.43-10.68 4.14(1.64) 2.16-7.32 < 5.20 -5.852 0.000*
LDL (mmol/L) 3.53(0.55) 1.36-6.85 2.15(0.85) 0.64-3.43 < 2.60 -5.846 0.000*
HDL (mmol/L) 0.81(0.19) 0.52-1.63 0.88(0.45) 0.39-1.50 ≥ 1.10 -2.155 0.031*
TG (mmol/L) 1.66(0.86) 0.60-3.40 1.32(0.71) 0.18-4.29 < 1.70 -3.236 0.001*
LDL:HDL 4.49(1.18) 1.77-7.61 2.55(1.31) 0.73-7.59 < 3.0 -5.788 0.000*
Non-HDL (mmol/L) 5.89(1.09) 3.66-9.78 3.42(1.48) 1.42-6.19 < 3.35 -5.845 0.000*
TC:HDL 8.61(2.42) 4.09-12.44 4.79(2.37) 2.32-14.77 < 4.0 -5.548 0.000*
ApoA1 (g/L) 1.37(0.37) 0.67-2.17 1.25(0.39) 0.77-2.27 Female: 
1.04-1.63
Male: 
1.09-1.72
-0.124 0.901
ApoB (g/L) 1.26(0.18) 0.84-2.41 0.86(0.19) 0.39-1.91 Female:
 0.6 -1.17
Male: 
0.66-1.33
-6.055 0.000*
ApoB:ApoA1 ratio 1.02(0.31) 0.52-2.10 0.69(0.17) 0.28-1.34 Female: < 0.7
Male: < 0.8
-5.855 0.000*
Wilcoxon Signed Rank Test; *p < 0.05 is significant 
y/o = years old; TC = total cholesterol; LDL = low density lipoprotein cholesterol; HDL = high density lipoprotein cholesterol; TG 
= triglyceride; ApoA1 = apolipoprotein A1; ApoB = apolipoprotein B
**Roche Diagnostic reference ranges for adults
Table VI. Comparison of median difference of lipid parameters (between first and follow up appointments) for statins 
(n = 118)
Parameter
Statin
Z p valueLovastatin
(n=73)
Simvastatin
(n=45)
Median 
Differencea
IQR Median
Differenceb
IQR
TC (mmol/L) -1.63 1.11 -2.89 1.43 -3.814 0.000*
LDL-C (mmol/L) -1.14 0.66 -1.51 0.96 -2.993 0.003*
HDL-C (mmol/L) +0.03 0.37 +0.03 0.49 -2.212 0.027*
TG (mmol/L) -0.59 0.63 -0.34 0.58 -1.960 0.050*
LDL:HDL Ratio -1.30 1.26 -1.65 1.72 -2.541 0.011*
Non-HDL-C (mmol/L) -1.74 1.14 -2.97 1.75 -4.343 0.000*
TC:HDL-C Ratio -1.72 2.06 -2.98  2.47 -3.646 0.000*
ApoB (g/L) -0.31 0.18 -0.50 0.10 -5.362  0.000*
ApoA1 (g/L) +0.07 0.22 +0.10 0.22 -2.720 0.007*
ApoB:ApoA1 Ratio -0.23 0.20 -0.37 0.31 -4.542 0.000*
Mann-Whitney Test; *p < 0.05 is significant
aMedian difference  in lipid parameters between first appointment and follow up for lovastatin
bMedian difference in lipid parameters between first appointment and follow up for simvastatin
TC = total cholesterol; LDL-C = low density lipoprotein; HDL-C = high density lipoprotein; TG = triglyceride; ApoB 
= apolipoprotein B; ApoA1 = apolipoprotein A1; IQR = interquartile range. 
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measures the cholesterol content of all atherogenic 
lipoproteins (LDL-C, IDL-C and VLDL-C) (12). Based on 
the results of the AMORIS and INTERHEART studies that 
further established apoB:apoA1 ratio risk ranges for CAD 
as in Table VII (13), though we did not stratify according 
to gender, our results showed that the study population 
was at high risk prior to treatment (median = 0.92) but 
reduced to moderate risk (median = 0.69) at follow up 
(Table III), a measure not revealed by conventional lipid 
profile.
However, the widespread use and application of 
apolipoproteins has been hampered by arbitrary 
treatment cut-offs, technical issues of laboratory testing, 
standardisation and the cost factor (12). Although the 
International Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) has achieved a consensus 
on a practical standardisation procedure, this will 
take time to incorporate these markers into national 
and international guidelines and to be implemented 
worldwide (14).
In the interim, as shown in this study, non-HDL-C also 
decreased on follow-up. Its initial median value in the 
study population was raised at 5.57 mmol/L, suggesting 
an increased risk of developing CVD (15). However, on 
follow-up post statin, it was of decreasing trend though 
not to the recommended value of < 3.35 mmol/L (15, 
16). As such, considering that it is not only a predictive 
marker of CAD but also an established secondary target 
for therapy in patients where the TG > 2.3 mmol/L (16, 
17), we propose that it should be included in all formal 
reports of lipid profile. The other benefits for its official 
implementation in standard reporting are i) being a 
calculated value, there is no added cost; ii) it can be 
measured in non-fasting sample and iii) increased non-
HDL-C with normal LDL-C may potentially detect 
subjects with raised apo B, LDL-C particle number and 
small dense LDL (17). Furthermore, with the increasing 
prevalence of metabolic syndrome, non-HDL is a more 
accurate risk predictor for CVD compared to when 
LDL-C is used alone in this subset of patients (18). 
Although this study had its strengths being a prospective 
study as it was able to establish a temporal relationship 
between the exposure and outcome of interests, its 
main limitation includes the lack of assessment of 
different types of statins as only two types of statins were 
prescribed. Furthermore, therapeutic lifestyle changes 
(diet and exercise) were not taken into account and may 
have confounded the results. Although the change in 
lipid parameters were significant post-statin treatment, 
some values were not within the target values. This 
could be due to the fact that a one month reassessment 
time frame may not truly reflect the final steady state 
lipid status of the subject.
CONCLUSIONS
In summary, this study shows that statins have varying 
biochemical effects on lipid parameters, with simvastatin 
showing significantly better effects than lovastatin. 
However, future studies should look at a longer follow-
up period that may reflect the steady state lipid status of 
patients on statins. Non-HDL value should be included in 
the standard lipid profile report given its ease of use and 
implementation as it’s both a marker of coronary artery 
disease (CAD) risk stratification as well as an established 
determinant of goal attainment during therapy.
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